000126608 001__ 126608
000126608 005__ 20240319081031.0
000126608 0247_ $$2doi$$a10.3390/v14030524
000126608 0248_ $$2sideral$$a134040
000126608 037__ $$aART-2022-134040
000126608 041__ $$aeng
000126608 100__ $$aHidalgo-Tenorio, Carmen
000126608 245__ $$aDOLAVI Real-Life Study of Dolutegravir Plus Lamivudine in Naive HIV-1 Patients (48 Weeks)
000126608 260__ $$c2022
000126608 5060_ $$aAccess copy available to the general public$$fUnrestricted
000126608 5203_ $$aReal-world data in naïve HIV-1 patients demonstrate that dolutegravir plus lamivudine in a multiple tablet regimen is effective, safe, and satisfactory; it causes moderately increasing weight and abdominal circumference and is administrable on a test-and-treat strategy. Background: Our objectives were to determine the real-life effectiveness and safety of DT with dolutegravir (50 mg/QD) plus lamivudine (300 mg/QD) in a multiple-tablet regimen (MTR) in naïve PLHIV followed up for 48 weeks and to evaluate the compliance and satisfaction of patients. Material and methods: An open, single-arm, multicenter, non-randomized clinical trial from May 2019 through September 2020 with a 48-week follow-up. Results: The study included 88 PLHIV patients (87.5% male) with a mean age of 35.9 years; 76.1% were MSM patients. The mean baseline CD4 was 516.4 cells/uL, with a viral load (VL) of 4.49 log10, and 11.4% were in the AIDS stage. DT started within 7 days of first specialist consultation in all patients and the same day in 84.1%; 3.4% had baseline resistance mutations (K103N, V106I + E138A, and V108I); 12.5% were lost to follow-up. At week 48, 86.3% had VL < 50 cop/uL by intention-to-treat analysis and 98.7% by per-protocol (PP) analysis. Virological failure (VF) was recorded in 1.1%, with no resistance mutation. One blip was detected in 5.2% without VF. Three reported anxiety, dizziness, and cephalgia, respectively, at week 4 and one reported insomnia at week 24; none reported adverse events at week 48. The mean weight was 4 kg higher at 48 weeks (p = 0.0001) and abdominal circumference 3 cm larger at 24 weeks (p = 0.022). No forgetfulness occurred in 98.7% of patients. Patient satisfaction was 90/100 at 4, 24, and 48 weeks. Conclusion: Real-world data demonstrate that dolutegravir plus lamivudine in MTR is effective, safe, and satisfactory, moderately increasing weight and abdominal circumference and administrable on a test-and-treat strategy.
000126608 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttp://creativecommons.org/licenses/by/3.0/es/
000126608 592__ $$a1.29$$b2022
000126608 590__ $$a4.7$$b2022
000126608 593__ $$aInfectious Diseases$$c2022$$dQ1
000126608 591__ $$aVIROLOGY$$b15 / 36 = 0.417$$c2022$$dQ2$$eT2
000126608 593__ $$aVirology$$c2022$$dQ2
000126608 594__ $$a7.1$$b2022
000126608 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000126608 700__ $$aPasquau, Juan
000126608 700__ $$aVinuesa, David
000126608 700__ $$aFerra, Sergio
000126608 700__ $$aTerrón, Alberto
000126608 700__ $$0(orcid)0000-0003-1436-4334$$aSanjoaquín, Isabel$$uUniversidad de Zaragoza
000126608 700__ $$aPayeras, Antoni
000126608 700__ $$aMartínez, Onofre J.
000126608 700__ $$aLópez-Ruz, Miguel Á.
000126608 700__ $$aOmar, Mohamed
000126608 700__ $$ade la Torre-Lima, Javier
000126608 700__ $$aLópez-Lirola, Ana
000126608 700__ $$aPalomares, Jesús
000126608 700__ $$aBlanco, José R.
000126608 700__ $$aMontero, Marta
000126608 700__ $$aGarcía-Vallecillos, Coral
000126608 7102_ $$11007$$2610$$aUniversidad de Zaragoza$$bDpto. Medicina, Psiqu. y Derm.$$cArea Medicina
000126608 773__ $$g14, 3 (2022), 524 [11 pp.]$$pVIRUSES-BASEL$$tVIRUSES-BASEL$$x1999-4915
000126608 8564_ $$s1368404$$uhttps://zaguan.unizar.es/record/126608/files/texto_completo.pdf$$yVersión publicada
000126608 8564_ $$s2764934$$uhttps://zaguan.unizar.es/record/126608/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000126608 909CO $$ooai:zaguan.unizar.es:126608$$particulos$$pdriver
000126608 951__ $$a2024-03-18-17:09:40
000126608 980__ $$aARTICLE